{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:32:59Z","timestamp":1788219179423,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118188","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:01:01Z","timestamp":1748228461000},"page":"118188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer"],"prefix":"10.1016","volume":"188","author":[{"given":"Frederico","family":"Furriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-9326","authenticated-orcid":false,"given":"Hugo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-0398","authenticated-orcid":false,"given":"Gabriela","family":"Sampaio-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Eloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4926","authenticated-orcid":false,"given":"Belmiro","family":"Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118188_bib1","unstructured":"J. Ferlay, M. Ervik, F. Lam, M. Laversanne, M. Colombet, L. Mery, M. Pi\u00f1eros, A. Znaor, I. Soerjomataram, F. Bray, Global cancer observatory: Cancer today, GLOBOCAN 2022. Int Agency Res Cancer. Published online 2024. https:\/\/gco.iarc.who.int\/today. (Accessed February 15, 2024)."},{"key":"10.1016\/j.biopha.2025.118188_bib2","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118188_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2025.118188_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/biomedicines10020411","article-title":"Immune-checkpoint inhibitors in advanced bladder cancer: seize the day","volume":"10","author":"Maiorano","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118188_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2025.118188_bib6","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.2147\/OTT.S221340","article-title":"The role of PD-1\/PD-L1 axis in Treg development and function: implications for cancer immunotherapy","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2025.118188_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118188_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118188_bib9","doi-asserted-by":"crossref","unstructured":"D. Ren,Y. Hua,B. Yu, X. Ye, Z. He, C. Li, J. Wang, Y. Mo, X. Wei, Y. Chen Y, Y. Zhou, Q. Liao, H. Wang, B. Xiang, M. Zhou, X. Li, G. Li, Y. Li, Z. Zeng, W. Xiong. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020 Jan 30;19(1):19. https:\/\/doi.org\/10.1186\/s12943-020-1144-6. Erratum in: Mol Cancer. 2020 Feb 14;19(1):31. https:\/\/doi.org\/10.1186\/s12943-020-01148-y.","DOI":"10.1186\/s12943-020-1144-6"},{"key":"10.1016\/j.biopha.2025.118188_bib10","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118188_bib11","first-page":"485","article-title":"Immune escape mechanisms and immunotherapy of urothelial bladder cancer","author":"Yang","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.biopha.2025.118188_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118188_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118188_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2025.118188_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/ni.3331","article-title":"CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors","volume":"17","author":"Kalekar","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2025.118188_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2018.10.016","article-title":"Production of extracellular adenosine by CD73+\u2009dendritic cells is crucial for induction of tolerance in contact hypersensitivity reactions","volume":"139","author":"Silva-Vilches","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.biopha.2025.118188_bib17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00262-020-02535-6","article-title":"Adenosine-producing regulatory B cells in head and neck cancer","volume":"69","author":"Jeske","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118188_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic regulation of macrophage polarization in cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2025.118188_bib19","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/OTT.S297272","article-title":"CD8+CD39+\u2009T cells mediate anti-tumor cytotoxicity in bladder cancer","volume":"14","author":"Zhu","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2025.118188_bib20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.18632\/oncotarget.28029","article-title":"High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer","volume":"12","author":"Ferreira","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118188_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/785461","article-title":"CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder cancer","volume":"2015","author":"Wettstein","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.biopha.2025.118188_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: An emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2025.118188_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118188_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118188_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti\u2013PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2025.118188_bib26","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118188_bib27","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1038\/s41467-023-38578-3","article-title":"Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118188_bib28","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1038\/s41467-022-34495-z","article-title":"Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118188_bib29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41596-018-0112-8","article-title":"A surgical orthotopic approach for studying the invasive progression of human bladder cancer","volume":"14","author":"Hiles","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2025.118188_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2025.118188_bib31","first-page":"15","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.biopha.2025.118188_bib32","doi-asserted-by":"crossref","first-page":"67.e1","DOI":"10.1016\/j.urolonc.2014.06.010","article-title":"Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non\u2013muscle-invasive bladder cancer","volume":"33","author":"Mano","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.biopha.2025.118188_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/cancers13020177","article-title":"CD73, tumor plasticity and immune evasion in solid cancers","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118188_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113066","article-title":"CD39 \u2013 A bright target for cancer immunotherapy","volume":"151","author":"Guo","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118188_bib35","doi-asserted-by":"crossref","first-page":"57327","DOI":"10.18632\/oncotarget.16905","article-title":"Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118188_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11302-005-5302-5","article-title":"Physiological roles for ecto-5\u2019-nucleotidase (CD73)","volume":"2","author":"Colgan","year":"2006","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2025.118188_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7150\/ijbs.87440","article-title":"Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion","volume":"20","author":"Lian","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118188_bib38","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1038\/s41467-023-38578-3","article-title":"Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118188_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-019-0728-3","article-title":"Downregulation of CD73 associates with T cell exhaustion in AML patients","volume":"12","author":"Kong","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118188_bib40","article-title":"CD73+CD8+\u2009T cells define a subset with anti-tumor potential in DLBCL patients","volume":"12","author":"Zhang","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2025.118188_bib41","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84508","article-title":"The CD73 immune checkpoint promotes tumor cell metabolic fitness","volume":"12","author":"Allard","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.biopha.2025.118188_bib42","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2025.118188_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/imcb.12251","article-title":"Pharmacological blockade of the CD39\/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease","volume":"97","author":"Geraghty","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118188_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2021.100093","article-title":"A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment","volume":"11","author":"Wei","year":"2021","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118188_bib45","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.2217\/fon-2020-0401","article-title":"CD38 as an immunomodulator in cancer","volume":"16","author":"Li","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2025.118188_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3892\/ol.2024.14722","article-title":"Role of ENPP1 in cancer pathogenesis: mechanisms and clinical implications (Review) (Review)","volume":"28","author":"Zhao","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2025.118188_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.633603","article-title":"CD39 and CD73 as promising therapeutic targets: What could be the limitations?","volume":"12","author":"Battastini","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118188_bib48","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.3390\/ijms20225698","article-title":"Inhibition of the adenosinergic pathway in cancer rejuvenates innate and adaptive immunity","volume":"20","author":"Azambuja","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118188_bib49","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1021\/acs.molpharmaceut.1c00448","article-title":"Immunotherapy strategy targeting programmed cell death ligand 1 and CD73 with macrophage-derived mimetic nanovesicles to treat bladder cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118188_bib50","series-title":"Experimental and Clinical Metastasis: A Comprehensive Review","author":"Burnier","year":"2013"},{"key":"10.1016\/j.biopha.2025.118188_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455469","article-title":"The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer","volume":"15","author":"Gardani","year":"2024","journal-title":"Front. Immunol."},{"issue":"29","key":"10.1016\/j.biopha.2025.118188_bib52","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:50:31Z","timestamp":1758124231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"alternative-id":["S0753332225003828"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118188","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118188"}}